Select a medication above to begin.
Leqembi (lecanemab-irmb)
lecanemab
Black Box Warnings .
Amyloid-Related Imaging Abnormalities (ARIA)
can cause ARIA w/ edema (ARIA-E) and ARIA w/ hemosiderin deposition (ARIA-H); incidence and timing vary; usually asymptomatic and occurs early in tx, though serious, life-threatening, or fatal events can occur; serious cerebral hemorrhage observed, incl. fatal; consider if focal neurologic deficits due to ARIA-E vs. ischemic stroke before admin. thrombolytic tx; apolipoprotein E epsilon 4 homozygotes have incr. ARIA incidence vs. heterozygotes and noncarriers; test for apolipoprotein E epsilon 4 status before tx start; before testing, discuss w/ patients ARIA risk across genotypes and implications of genetic testing results; inform patients they may receive tx w/o genotype testing, but it cannot be determined if they are apolipoprotein E epsilon 4 homozygotes at incr. ARIA risk; consider benefit vs. risk when deciding to initiate tx
Adult Dosing .
Dosage forms: INJ
Special Note
- [drug name clarification]
- Info: nonproprietary name = lecanemab-irmb
Alzheimer disease, mild cognitive impairment or mild dementia
- [initial tx]
- Dose: 10 mg/kg/dose IV q2wk x18mo; Info: for patients w/ confirmed amyloid beta pathology; use ABW to calculate dose; see pkg insert for dose interruptions based on brain MRI and symptom severity in patients w/ amyloid-related imaging abnormalities; consider premed w/ antihistamine, acetaminophen, NSAID, or corticosteroid if infusion rxn occurs
- [maintenance tx]
- Dose: 10 mg/kg/dose IV q2wk or q4wk; Start: 2wk after last initial dose; Info: for patients w/ confirmed amyloid beta pathology; use ABW to calculate dose; see pkg insert for dose interruptions based on brain MRI and symptom severity in patients w/ amyloid-related imaging abnormalities; consider premed w/ antihistamine, acetaminophen, NSAID, or corticosteroid if infusion rxn occurs; may switch between IV and SC forms during maintenance tx, start new dosing regimen 1wk after last maintenance dose; SC injectable form not avail. for this brand, see other lecanemab-irmb product
renal dosing
- [not defined]
- renal impairment: not defined
- HD/PD: not defined
hepatic dosing
- [not defined]
Peds Dosing .
Peds dosing is currently unavailable or not applicable for this drug.